RJA
TCRT icon

Raymond James & Associates’s Alaunos Therapeutics TCRT Stock Holding History

Raymond James & Associates’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-112
Closed -$1.19K – 4033
2023
Q4 		$1.19K Sell
112
-70
-38% -$843 ﹤0.01% 3819
2023
Q3 		$3.59K Sell
182
-226
-55% -$9.74K ﹤0.01% 3780
2023
Q2 		$31.2K Hold
408
– – ﹤0.01% 3743
2023
Q1 		$38.6K Sell
408
-36
-8% -$3.43K ﹤0.01% 3753
2022
Q4 		$43.3K Buy
444
+3
+0.7% +$435 ﹤0.01% 3730
2022
Q3 		$114K Sell
441
-50
-10% -$14.5K ﹤0.01% 3584
2022
Q2 		$91K Sell
491
-3
-0.6% -$287 ﹤0.01% 3695
2022
Q1 		$48K Sell
494
-66
-12% -$8.47K ﹤0.01% 3916
2021
Q4 		$92K Buy
560
+10
+2% +$2.2K ﹤0.01% 3874
2021
Q3 		$150K Sell
550
-47
-8% -$14.4K ﹤0.01% 3741
2021
Q2 		$237K Sell
597
-44
-7% -$20.5K ﹤0.01% 3586
2021
Q1 		$346K Sell
641
-21
-3% -$13.1K ﹤0.01% 3263
2020
Q4 		$250K Sell
662
-49
-7% -$19.5K ﹤0.01% 3244
2020
Q3 		$269K Sell
711
-14
-2% -$6.18K ﹤0.01% 3021
2020
Q2 		$357K Buy
725
+34
+5% +$15.2K ﹤0.01% 2820
2020
Q1 		$254K Buy
691
+218
+46% +$113K ﹤0.01% 2877
2019
Q4 		$335K Buy
473
+146
+45% +$100K ﹤0.01% 3021
2019
Q3 		$210K Buy
327
+6
+2% +$4.76K ﹤0.01% 3231
2019
Q2 		$281K Sell
321
-81
-20% -$55.7K ﹤0.01% 3051
2019
Q1 		$232K Buy
402
+27
+7% +$11.3K ﹤0.01% 3144
2018
Q4 		$105K Sell
375
-12
-3% -$4.74K ﹤0.01% 3298
2018
Q3 		$186K Sell
387
-2
-0.5% -$858 ﹤0.01% 3322
2018
Q2 		$176K Buy
389
+244
+168% +$155K ﹤0.01% 3298
2018
Q1 		$85K Hold
145
– – ﹤0.01% 3286
2017
Q4 		$90K Sell
145
-90
-38% -$64.7K ﹤0.01% 3223
2017
Q3 		$216K Hold
235
– – ﹤0.01% 2998
2017
Q2 		$219K Sell
235
-7
-3% -$6.86K ﹤0.01% 2926
2017
Q1 		$230K Buy
242
+26
+12% +$24.2K ﹤0.01% 2844
2016
Q4 		$173K Sell
216
-23
-10% -$20.7K ﹤0.01% 2918
2016
Q3 		$202K Sell
239
-84
-26% -$67.5K ﹤0.01% 2844
2016
Q2 		$266K Sell
323
-8
-2% -$8.71K ﹤0.01% 2479
2016
Q1 		$369K Sell
331
-12
-3% -$12.3K ﹤0.01% 2216
2015
Q4 		$427K Buy
343
+189
+123% +$313K ﹤0.01% 2066
2015
Q3 		$208K Buy
154
+18
+13% +$29.7K ﹤0.01% 2246
2015
Q2 		$244K Sell
136
-190
-58% -$295K ﹤0.01% 2328
2015
Q1 		$527K Buy
+326
New +$483K ﹤0.01% 2016

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return

Raymond James & Associates's TCRT Position: Q1 2024 in Review

Raymond James & Associates sold out of Alaunos Therapeutics (TCRT) in Q1 2024, closing a stake of 112 shares — an estimated $1.19K sold.

Raymond James & Associates first reported a position in TCRT in Q1 2015 and held it in 36 quarters. The position peaked at $527K in Q1 2015. 45 funds tracked by Wall St. Rank hold TCRT as of Q1 2024.

  • Raymond James & Associates reported no remaining Alaunos Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Raymond James & Associates sold 112 Alaunos Therapeutics shares in Q1 2024, an estimated $1.19K.
  • Raymond James & Associates first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 36 quarters.
  • Raymond James & Associates's Alaunos Therapeutics position peaked at $527K in Q1 2015.
  • 45 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2024.

Based on Raymond James & Associates's 13F filing for Q1 2024, filed 22 Apr 2024.